Vasoactive Intestinal Peptide (VIP) - Induced pulmonary vasodilation mediated by EDRF/NO in isolated perfused rat lungs

S. Iwabuchi, S. Ono, J. Funata, Y. Hoshikawa, S. Ueda, Y. Ashino, T. Tanita, S. Fujimura, K. Koike

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

We studied the effects of Vasoactive Intestinal Peptide (VIP) on the pulmonary circulation in isolated perfused rat lungs. VIP caused pulmonary vasodilation in a dose-dependent manner. This effect was inhibited by pretreatment with L-Nω nitro-arginine (L-NNA), a competitive inhibitor of endothelium-derived relaxing factor (EDRF/NO), but not by meclofenamate, a cyclooxygenase inhibitor. Addition of L-arginine, a substrate of EDRF/NO, after treatment with L-NNA reversed VIP-induced pulmonary vasodilation. These results indicate that VIP causes pulmonary vasodilation, and they suggest a role for EDRF/NO in VIP-induced pulmonary vasodilation in isolated rat lungs.

Original languageEnglish
Pages (from-to)262-267
Number of pages6
JournalJapanese Journal of Thoracic Diseases
Volume33
Issue number3
Publication statusPublished - 01-01-1995
Externally publishedYes

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Pulmonary and Respiratory Medicine

Cite this

Iwabuchi, S., Ono, S., Funata, J., Hoshikawa, Y., Ueda, S., Ashino, Y., Tanita, T., Fujimura, S., & Koike, K. (1995). Vasoactive Intestinal Peptide (VIP) - Induced pulmonary vasodilation mediated by EDRF/NO in isolated perfused rat lungs. Japanese Journal of Thoracic Diseases, 33(3), 262-267.